CTOs on the Move

Centrix Inc.

www.centrixdental.com

 
Centrix, Inc. manufactures and sells a complete line of dental products to the dental industry. We do this through a hybrid marketing channel of both direct and dealer distributor sales.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Hitachi Chemical Research Ctr.

Hitachi Chemical Research Ctr. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Copper Queen Community Hospital

Copper Queen Community Hospital has a rich heritage, dating back to the 1880s when it operated as a part of the mining community, so important to the history of Bisbee.

DNA2.0

DNA2.0 is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Menlo Park, CA. To find more information about DNA2.0, please visit www.dnatwopointo.com

Physicians Health Choice

Physicians Health Choice is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Discovery Laboratories Inc

Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.